Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00698724 · ClinicalTrials.gov registry record · Phase 4
Comparing Optical Coherence Tomography (OCT) and Visual Acuity Outcomes in Subjects Undergoing Cataract Surgery, Who Receive Xibrom Ophthalmic Solution and Standard Presurgical Care vs. Xibrom Ophthalmic Solution Plus Prednisolone Acetate 1% and Standard Presurgical Care
A Phase 4 study, sponsored by Bp Consulting.
- Completed
- Registry status
- Phase 4
- Development phase
- 200
- Enrollment target
NCT00698724 is a Phase 4 study that has completed, run by Bp Consulting. The registered enrollment target is 200 participants.
The verdict
NCT00698724, a Phase 4 study, has completed, sponsored by Bp Consulting.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 200 participants
- Enrollment target
Study Summary
To compare the efficacy of twice-daily topical bromfenac (Xibrom) ophthalmic solution alone versus twice-daily topical Xibrom with prednisolone acetate 1% three-times daily on visual acuity and OCT measurements.
Interventions
- DRUG Xibrom, and Optive
- DRUG Xibrom and Pred Forte
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 200 participants |
| Start Date | 2008-06 |
| Est. Completion | 2009-06 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00698724
The ClinicalTrials.gov registry entry for NCT00698724 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 200 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bp Consulting, which has 10 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Xibrom, and Optive is the first listed.
NCT00698724 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00698724 about?
NCT00698724 is a clinical study titled "Comparing Optical Coherence Tomography (OCT) and Visual Acuity Outcomes in Subjects Undergoing Cataract Surgery, Who Receive Xibrom Ophthalmic Solution and Standard Presurgical Care vs. Xibrom Ophthalmic Solution Plus Prednisolone Acetate 1% and Standard Presurgical Care". To compare the efficacy of twice-daily topical bromfenac (Xibrom) ophthalmic solution alone versus twice-daily topical Xibrom with prednisolone acetate 1% three-times daily on visual acuity and OCT measurements.
What is the current status of trial NCT00698724?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 200 participants. The study started on 2008-06. Estimated completion is 2009-06.
What interventions are being tested in trial NCT00698724?
The interventions under investigation include: Xibrom, and Optive (DRUG), Xibrom and Pred Forte (DRUG).
Who is sponsoring clinical trial NCT00698724?
This trial is sponsored by Bp Consulting, which has 10 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.